FDA's America First Agenda: Reshaping Global Pharma Manufacturing

An in-depth examination of how FDA's user fee negotiations, "America First" proposals, and Pre-Check Program are incentivizing domestic investment while creating nuanced barriers for CMOs and international manufacturers navigating US market access. These policy shifts extend through 2030-2031 and are fundamentally altering global pharmaceutical investment patterns and manufacturing location decisions.

- User Fee Reauthorization Impacts: How five-year funding cycles and domestic manufacturing incentives are reshaping investment priorities and facility planning

- Pre-Check Program Limitations: Why the program favors greenfield sites over facility expansions, creating unintended consequences for CMOs seeking efficient capacity additions

- Global Manufacturing Strategy Implications: How European and Asian companies must adapt their US market entry approaches amid shifting regulatory incentives